{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T01:04:56Z","timestamp":1784250296230,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503957"],"award-info":[{"award-number":["82503957"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300791"],"award-info":[{"award-number":["82300791"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2023JJ30783"],"award-info":[{"award-number":["2023JJ30783"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2023JJ40814"],"award-info":[{"award-number":["2023JJ40814"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Scientific Research Program of FuRong Laboratory","award":["2023SK2104"],"award-info":[{"award-number":["2023SK2104"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-026-04347-7","type":"journal-article","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T13:42:32Z","timestamp":1779630152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["NUDT1 drives osteosarcoma progression and serves as a robust predictor of clinical outcomes"],"prefix":"10.1186","volume":"26","author":[{"given":"Zhe","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianming","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixi","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,24]]},"reference":[{"issue":"2","key":"4347_CR1","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.cell.2024.12.005","volume":"188","author":"J Espejo Valle-Inclan","year":"2025","unstructured":"Espejo Valle-Inclan J, De Noon S, Trevers K, Elrick H, van Belzen I, Zumalave S, et al. Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution. Cell. 2025;188(2):352\u2013e7022. https:\/\/doi.org\/10.1016\/j.cell.2024.12.005.","journal-title":"Cell"},{"issue":"1","key":"4347_CR2","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12943-024-02105-9","volume":"23","author":"S Yu","year":"2024","unstructured":"Yu S, Yao X. Advances on immunotherapy for osteosarcoma. Mol Cancer. 2024;23(1):192. https:\/\/doi.org\/10.1186\/s12943-024-02105-9.","journal-title":"Mol Cancer"},{"issue":"1","key":"4347_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41392-025-02250-7","volume":"10","author":"B Liu","year":"2025","unstructured":"Liu B, Li W, Zhang W, Feng C, Wan L, He S, et al. PKMYT1 kinase ameliorates cisplatin sensitivity in osteosarcoma. Signal Transduct Target Ther. 2025;10(1):165. https:\/\/doi.org\/10.1038\/s41392-025-02250-7.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"4347_CR4","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/nrc3838","volume":"14","author":"M Kansara","year":"2014","unstructured":"Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of osteosarcoma. Nat Rev Cancer. 2014;14(11):722\u201335. https:\/\/doi.org\/10.1038\/nrc3838.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"4347_CR5","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41571-021-00519-8","volume":"18","author":"J Gill","year":"2021","unstructured":"Gill J, Gorlick R. Advancing therapy for osteosarcoma. Nat Rev Clin Oncol. 2021;18(10):609\u201324. https:\/\/doi.org\/10.1038\/s41571-021-00519-8.","journal-title":"Nat Rev Clin Oncol"},{"issue":"22","key":"4347_CR6","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1056\/NEJMra2103423","volume":"385","author":"PS Meltzer","year":"2021","unstructured":"Meltzer PS, Helman LJ. New Horizons in the Treatment of Osteosarcoma. N Engl J Med. 2021;385(22):2066\u201376. https:\/\/doi.org\/10.1056\/NEJMra2103423.","journal-title":"N Engl J Med"},{"key":"4347_CR7","doi-asserted-by":"publisher","unstructured":"Misiak R, Bialkowski K, Dondajewska E. Clinical Significance of NUDT1 (MTH1) Across Cancer Types. Int J Mol Sci. 2025;26(11). https:\/\/doi.org\/10.3390\/ijms26115137.","DOI":"10.3390\/ijms26115137"},{"key":"4347_CR8","doi-asserted-by":"publisher","first-page":"103394","DOI":"10.1016\/j.redox.2024.103394","volume":"77","author":"A Taiyab","year":"2024","unstructured":"Taiyab A, Ashraf A, Sulaimani MN, Rathi A, Shamsi A, Hassan MI. Role of MTH1 in oxidative stress and therapeutic targeting of cancer. Redox Biol. 2024;77:103394. https:\/\/doi.org\/10.1016\/j.redox.2024.103394.","journal-title":"Redox Biol"},{"issue":"12","key":"4347_CR9","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1016\/j.apsb.2020.02.012","volume":"10","author":"Y Yin","year":"2020","unstructured":"Yin Y, Chen F. Targeting human MutT homolog 1 (MTH1) for cancer eradication: current progress and perspectives. Acta Pharm Sin B. 2020;10(12):2259\u201371. https:\/\/doi.org\/10.1016\/j.apsb.2020.02.012.","journal-title":"Acta Pharm Sin B"},{"key":"4347_CR10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.freeradbiomed.2021.10.004","volume":"176","author":"K Bialkowski","year":"2021","unstructured":"Bialkowski K, Szpila A. Specific 8-oxo-dGTPase activity of MTH1 (NUDT1) protein as a quantitative marker and prognostic factor in human colorectal cancer. Free Radic Biol Med. 2021;176:257\u201364. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2021.10.004.","journal-title":"Free Radic Biol Med"},{"issue":"8","key":"4347_CR11","doi-asserted-by":"publisher","first-page":"7363","DOI":"10.18632\/aging.103083","volume":"12","author":"Q Ou","year":"2020","unstructured":"Ou Q, Ma N, Yu Z, Wang R, Hou Y, Wang Z, et al. Nudix hydrolase 1 is a prognostic biomarker in hepatocellular carcinoma. Aging. 2020;12(8):7363\u201379. https:\/\/doi.org\/10.18632\/aging.103083.","journal-title":"Aging"},{"key":"4347_CR12","doi-asserted-by":"publisher","unstructured":"Magkouta SF, Pappas AG, Vaitsi PC, Agioutantis PC, Pateras IS, Moschos CA, et al. MTH1 favors mesothelioma progression and mediates paracrine rescue of bystander endothelium from oxidative damage. JCI Insight. 2020;5(12). https:\/\/doi.org\/10.1172\/jci.insight.134885.","DOI":"10.1172\/jci.insight.134885"},{"key":"4347_CR13","doi-asserted-by":"publisher","first-page":"102704","DOI":"10.1016\/j.ebiom.2020.102704","volume":"53","author":"B Moukengue","year":"2020","unstructured":"Moukengue B, Brown HK, Charrier C, Battaglia S, Baud\u2019huin M, Quillard T, et al. TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model. EBioMedicine. 2020;53:102704. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102704.","journal-title":"EBioMedicine"},{"key":"4347_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.actbio.2020.04.009","volume":"109","author":"X Huang","year":"2020","unstructured":"Huang X, Chen J, Wu W, Yang W, Zhong B, Qing X, et al. Delivery of MutT homolog 1 inhibitor by functionalized graphene oxide nanoparticles for enhanced chemo-photodynamic therapy triggers cell death in osteosarcoma. Acta Biomater. 2020;109:229\u201343. https:\/\/doi.org\/10.1016\/j.actbio.2020.04.009.","journal-title":"Acta Biomater"},{"issue":"12","key":"4347_CR15","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8.","journal-title":"Genome Biol"},{"issue":"1A","key":"4347_CR16","doi-asserted-by":"publisher","first-page":"A68","DOI":"10.5114\/wo.2014.47136","volume":"19","author":"K Tomczak","year":"2015","unstructured":"Tomczak K, Czerwinska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1A):A68\u201377. https:\/\/doi.org\/10.5114\/wo.2014.47136.","journal-title":"Contemp Oncol (Pozn)"},{"issue":"14","key":"4347_CR17","doi-asserted-by":"publisher","first-page":"e23783","DOI":"10.1096\/fj.202400622RR","volume":"38","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Liu B, Lin Z, Mei L, Chen R, Li Z. SPP1 could be an immunological and prognostic biomarker: From pan-cancer comprehensive analysis to osteosarcoma validation. FASEB J. 2024;38(14):e23783. https:\/\/doi.org\/10.1096\/fj.202400622RR.","journal-title":"FASEB J"},{"issue":"5","key":"4347_CR18","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1002\/mco2.369","volume":"4","author":"C Tu","year":"2023","unstructured":"Tu C, Liu B, Li C, Feng C, Wang H, Zhang H, et al. Integrative analysis of TROAP with molecular features, carcinogenesis, and related immune and pharmacogenomic characteristics in soft tissue sarcoma. MedComm. 2023;4(5):e369. https:\/\/doi.org\/10.1002\/mco2.369.","journal-title":"MedComm"},{"issue":"3","key":"4347_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4347_CR20","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.2005.04.063","volume":"23","author":"B Kempf-Bielack","year":"2005","unstructured":"Kempf-Bielack B, Bielack SS, Jurgens H, Branscheid D, Berdel WE, Exner GU, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2005;23(3):559\u201368. https:\/\/doi.org\/10.1200\/JCO.2005.04.063.","journal-title":"J Clin Oncol"},{"issue":"27","key":"4347_CR21","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1200\/JCO.2014.59.4895","volume":"33","author":"MS Isakoff","year":"2015","unstructured":"Isakoff MS, Bielack SS, Meltzer P, Gorlick R, Osteosarcoma. Current Treatment and a Collaborative Pathway to Success. J Clin Oncol. 2015;33(27):3029\u201335. https:\/\/doi.org\/10.1200\/JCO.2014.59.4895.","journal-title":"J Clin Oncol"},{"key":"4347_CR22","doi-asserted-by":"publisher","first-page":"114545","DOI":"10.1016\/j.intimp.2025.114545","volume":"154","author":"B Liu","year":"2025","unstructured":"Liu B, Li C, He S, Li Z, Wang H, Feng C, et al. Ubiquitin-conjugating enzyme E2S (UBE2S) as a prognostic biomarker and regulator of tumorigenesis in osteosarcoma. Int Immunopharmacol. 2025;154:114545. https:\/\/doi.org\/10.1016\/j.intimp.2025.114545.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"4347_CR23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.celrep.2014.03.003","volume":"7","author":"X Chen","year":"2014","unstructured":"Chen X, Bahrami A, Pappo A, Easton J, Dalton J, Hedlund E, et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep. 2014;7(1):104\u201312. https:\/\/doi.org\/10.1016\/j.celrep.2014.03.003.","journal-title":"Cell Rep"},{"issue":"1","key":"4347_CR24","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41467-020-14646-w","volume":"11","author":"CC Wu","year":"2020","unstructured":"Wu CC, Beird HC, Andrew Livingston J, Advani S, Mitra A, Cao S, et al. Immuno-genomic landscape of osteosarcoma. Nat Commun. 2020;11(1):1008. https:\/\/doi.org\/10.1038\/s41467-020-14646-w.","journal-title":"Nat Commun"},{"issue":"11","key":"4347_CR25","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","volume":"18","author":"HA Tawbi","year":"2017","unstructured":"Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493\u2013501. https:\/\/doi.org\/10.1016\/S1470-2045(17)30624-1.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4347_CR26","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1186\/s12885-018-4332-7","volume":"18","author":"HHK Abbas","year":"2018","unstructured":"Abbas HHK, Alhamoudi KMH, Evans MD, Jones GDD, Foster SS. MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: more bad news than good? BMC Cancer. 2018;18(1):423. https:\/\/doi.org\/10.1186\/s12885-018-4332-7.","journal-title":"BMC Cancer"},{"issue":"11","key":"4347_CR27","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1093\/neuonc\/noy071","volume":"20","author":"L Pudelko","year":"2018","unstructured":"Pudelko L, Edwards S, Balan M, Nyqvist D, Al-Saadi J, Dittmer J, et al. An orthotopic glioblastoma animal model suitable for high-throughput screenings. Neuro Oncol. 2018;20(11):1475\u201384. https:\/\/doi.org\/10.1093\/neuonc\/noy071.","journal-title":"Neuro Oncol"},{"issue":"1","key":"4347_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022;12(1):31\u201346. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1059.","journal-title":"Cancer Discov"},{"issue":"7495","key":"4347_CR29","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nature13181","volume":"508","author":"H Gad","year":"2014","unstructured":"Gad H, Koolmeister T, Jemth AS, Eshtad S, Jacques SA, Strom CE, et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature. 2014;508(7495):215\u201321. https:\/\/doi.org\/10.1038\/nature13181.","journal-title":"Nature"},{"key":"4347_CR30","doi-asserted-by":"publisher","unstructured":"Cascini C, Chiodoni C. The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response. Cells. 2021;10(7). https:\/\/doi.org\/10.3390\/cells10071668.","DOI":"10.3390\/cells10071668"},{"issue":"6","key":"4347_CR31","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang CH, Qiu J, O\u2019Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015;162(6):1229\u201341. https:\/\/doi.org\/10.1016\/j.cell.2015.08.016.","journal-title":"Cell"},{"issue":"6","key":"4347_CR32","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16(6):356\u201371. https:\/\/doi.org\/10.1038\/s41571-019-0175-7.","journal-title":"Nat Rev Clin Oncol"},{"issue":"21","key":"4347_CR33","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.1158\/1078-0432.CCR-23-0257","volume":"29","author":"M Casanova","year":"2023","unstructured":"Casanova M, Bautista F, Campbell-Hewson Q, Makin G, Marshall LV, Verschuur AC, et al. Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent\/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study. Clin Cancer Res. 2023;29(21):4341\u201351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0257.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 4","key":"4347_CR34","doi-asserted-by":"publisher","first-page":"iv79","DOI":"10.1093\/annonc\/mdy310","volume":"29","author":"PG Casali","year":"2018","unstructured":"Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, et al. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv79\u201395. https:\/\/doi.org\/10.1093\/annonc\/mdy310.","journal-title":"Ann Oncol"},{"issue":"10","key":"4347_CR35","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrc1977","volume":"6","author":"Y Pommier","year":"2006","unstructured":"Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006;6(10):789\u2013802. https:\/\/doi.org\/10.1038\/nrc1977.","journal-title":"Nat Rev Cancer"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04347-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04347-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04347-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:45:44Z","timestamp":1784249144000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-026-04347-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,24]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4347"],"URL":"https:\/\/doi.org\/10.1186\/s12935-026-04347-7","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,24]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Review Board of the Second Xiangya Hospital, and all participants provided written informed consent. Ethical approval for this study was granted under the Second Xiangya Hospital Ethical Committee (Serial number: 2022303).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"266"}}